Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: amylin receptor metabolic pharmacology
Also known as: LY3841136
Eloralintide or LY3841136 is a selective long-acting amylin-receptor agonist in clinical development. Phase 1 studied single doses from 0.04-12 mg and later once-weekly multiple dosing. Clinical trial formulation and dose strengths should not be equated with gray-market lyophilized vials.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Phase 1 publications, trial registry, and sponsor Phase 2 disclosure
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
0.04-12 mg as a single ascending dose
Context: NCT05295940 and PMID 41109426
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.
3 mg weekly or escalation through 3 mg 6 mg and 9 mg
Context: Phase 2 program NCT06230523
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
The listed dose strengths are clinical-study levels rather than verified commercial SKUs. Eloralintide remains investigational as of July 2026.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.